JOHN JOHNSON
CIK 1410781 · Executive Chairman · last filed 2026-06-26
JOHN JOHNSON is an Executive Chairman who has filed 104 SEC Form 4 insider transactions across 13 companies since 2007. The most recent filing, for AXGN, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$3.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.64M
13
104
-$3.23M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AXGN | Director | 14,150 | $42.25 | $597.8K | -$1.91M | 12 | 2026-06-26 |
| XERS | Director | 683,083 | $8.38 | $5.72M | -$1.85M | 10 | 2026-06-05 |
| VSTM | Director | 52,666 | $6.08 | $320.2K | $0 | 10 | 2026-05-26 |
| Applied Therapeutics, Inc. (APLT) Delisted | Executive Chairman | 500,000 | $0.10 | $51.5K | $0 | 1 | 2024-12-20 |
| Strongbridge Biopharma plc (SBBP) Delisted | Chief Executive Officer | 0 | $2.00 | $0 | $0 | 11 | 2021-10-06 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 0 | — | — | $0 | 8 | 2020-07-02 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Chief Executive Officer | 37,400 | — | — | -$72.4K | 5 | 2019-07-02 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 5 | 2018-02-13 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Director | — | $15.00 | — | $0 | 1 | 2018-02-05 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Director | 10,000 | — | — | $0 | 6 | 2017-01-05 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | Director | — | — | — | $0 | 2 | 2012-08-09 |
| SAVIENT PHARMACEUTICALS INC (SVNT) Delisted | Chief Executive Officer | 256,350 | — | — | $110.5K | 6 | 2012-01-04 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | CEO | 0 | — | — | $500.0K | 4 | 2008-11-24 |
Recent Filings
104 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | AXGN | Grant (A) | — | $0 | EDGAR |
| 2026-06-23 | AXGN | Exer (M) | +14,150 | $0 | EDGAR |
| 2026-06-05 | XERS | Mixed | +9,193 | -$91.4K | EDGAR |
| 2026-06-04 | XERS | Notice (144) | −15,000 | -$88.3K | EDGAR |
| 2026-05-26 | VSTM | Grant (A) | +36,000 | $0 | EDGAR |
| 2026-05-08 | AXGN | Mixed | — | -$400.2K | EDGAR |
| 2026-05-07 | AXGN | Notice (144) | −11,050 | -$478.0K | EDGAR |
| 2025-12-19 | XERS | Notice (144) | −135,402 | -$977.0K | EDGAR |
| 2025-12-19 | XERS | Sell (S) | −135,400 | -$977.0K | EDGAR |
| 2025-12-10 | AXGN | Mixed | −24,943 | -$1.26M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.